Abstract
Contrast agents that traverse the pulmonary vascular bed after intravenous injection can enhance echocardiographic images of the left ventricular cavity and myocardium. One such agent, MRX115 (Aerosomes; ImaRx Pharmaceutical, Tucson, Ariz), enhanced visualization of the left ventricular cavity, wall motion, and myocardial tissue at baseline and during left anterior descending coronary artery occlusion in pigs (1) and rhesus monkeys (2). Work with this agent has been expanded to human studies. This report presents results from our institution that are part of a phase II, placebo-controlled, single-blinded, randomized trial of MRX115 for left ventricular cavity and myocardial perfusion imaging. The objectives of this study were, in patients referred for diagnostic echocardiography, to (a) establish the safety and tolerability of MRX115 and (b) demonstrate efficacy of MRX115 to enhance visualizatiign of the left ventricular cavity and myocardial tissue during echocardiographic imaging.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
